Suppr超能文献

熊去氧胆酸对原发性胆汁性肝硬化早期患者胆汁酸代谢的影响

Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis.

作者信息

Mazzella G, Parini P, Bazzoli F, Villanova N, Festi D, Aldini R, Roda A, Cipolla A, Polimeni C, Tonelli D

机构信息

Dipartimento di scienze farmaceutiche, University of Bologna, Italy.

出版信息

Dig Dis Sci. 1993 May;38(5):896-902. doi: 10.1007/BF01295917.

Abstract

Ursodeoxycholic acid has been proposed for the treatment of primary biliary cirrhosis. The aim of this study was to evaluate the effect of ursodeoxycholic acid administration on bile acid metabolism in patients with early-stage primary biliary cirrhosis. Biliary bile acid composition, primary bile acid pool sizes, synthesis, and fractional turnover rate were measured before and after four weeks of ursodeoxycholic acid administration (600 mg/day) in nine patients with biopsy-proven primary biliary cirrhosis (stages I-III). Molar percentages of chenodeoxycholic, cholic, and deoxycholic acids in bile were significantly decreased by ursodeoxycholic acid administration, while its biliary concentration increased to 34.2% at the end of the same four-week period. The cholic and chenodeoxycholic acid pools decreased, although not significantly, while the deoxycholic acid pool was reduced by 60% (from 0.7 +/- 0.12 to 0.29 +/- 0.07 mmol, P < 0.002). Primary bile acid synthesis was slightly increased, and fractional turnover rate was significantly increased. The conversion rate of cholic to deoxycholic acid was measured and found to be significantly increased (P < 0.05) after ursodeoxycholic acid administration; however, serum levels of both free and conjugated deoxycholic acid were significantly decreased (from 23.2 +/- 9.7 to 3.8 +/- 1.9 mumol/liter, P < 0.001). We conclude that in patients with primary biliary cirrhosis, ursodeoxycholic acid administration replaces endogenous bile acids in the enterohepatic circulation by increasing bile acid fractional turnover rate without significant increments of their hepatic synthesis.

摘要

熊去氧胆酸已被提议用于治疗原发性胆汁性肝硬化。本研究的目的是评估熊去氧胆酸给药对早期原发性胆汁性肝硬化患者胆汁酸代谢的影响。在9例经活检证实为原发性胆汁性肝硬化(I - III期)的患者中,测量了熊去氧胆酸给药(600毫克/天)四周前后的胆汁胆汁酸组成、初级胆汁酸池大小、合成及分数周转率。熊去氧胆酸给药后,胆汁中鹅去氧胆酸、胆酸和脱氧胆酸的摩尔百分比显著降低,而在同一四周期末其胆汁浓度增加至34.2%。胆酸和鹅去氧胆酸池有所减少,虽不显著,但脱氧胆酸池减少了60%(从0.7±0.12毫摩尔降至0.29±0.07毫摩尔,P<0.002)。初级胆汁酸合成略有增加,分数周转率显著增加。测量了胆酸向脱氧胆酸的转化率,发现熊去氧胆酸给药后显著增加(P<0.05);然而,游离和结合脱氧胆酸的血清水平均显著降低(从23.2±9.7微摩尔/升降至3.8±1.9微摩尔/升,P<0.001)。我们得出结论,在原发性胆汁性肝硬化患者中,熊去氧胆酸给药通过增加胆汁酸分数周转率而不显著增加其肝脏合成,从而在肠肝循环中替代内源性胆汁酸。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验